Dasatinib is a tablet which works by blocking the signals in these abnormal lymphocytes which causes them to grow and divide, causing these cancer cells to die. As children with philadelphia chromosome positive ALL are less likely to be cured by chemotherapy alone, adding dasatinib to the treatment programme, this may slow the progress of ALL and relieve symptoms.
Dasatinib (Sprycel) tablets for children with type II variation, philadelphia positive acute lymphoblastic leukaemia
Interventions:
Dasatinib (Sprycel; BMS 354825; dasatinib monohydrate)
Indications:
Acute lymphoblastic leukaemia (ALL)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2017